S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
Log in
CVE:IGX

IntelGenx Technologies Corp. (IGX.V) Stock Forecast, Price & News

C$0.32
+0.01 (+3.23 %)
(As of 01/21/2021 01:18 PM ET)
Add
Compare
Today's Range
C$0.32
Now: C$0.32
C$0.32
50-Day Range
C$0.00
MA: C$0.30
C$0.39
52-Week Range
C$0.16
Now: C$0.32
C$0.62
Volume38,340 shs
Average Volume30,204 shs
Market CapitalizationC$35.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral thin film products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, and INT0040/2014. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Insud Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

MarketRank

Overall MarketRank

0.52 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-331-7440
Employees48

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$822,000.00
Cash FlowC$0.01 per share
Book ValueC$0.00 per share

Profitability

Miscellaneous

Market CapC$35.28 million
Next Earnings Date3/25/2021 (Estimated)
OptionableNot Optionable
C$0.32
+0.01 (+3.23 %)
(As of 01/21/2021 01:18 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IGX News and Ratings via Email

Sign-up to receive the latest news and ratings for IGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IntelGenx Technologies Corp. (IGX.V) (CVE:IGX) Frequently Asked Questions

How has IntelGenx Technologies Corp. (IGX.V)'s stock been impacted by COVID-19?

IntelGenx Technologies Corp. (IGX.V)'s stock was trading at C$0.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IGX shares have decreased by 40.7% and is now trading at C$0.32.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than IntelGenx Technologies Corp. (IGX.V)?

Wall Street analysts have given IntelGenx Technologies Corp. (IGX.V) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IntelGenx Technologies Corp. (IGX.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IntelGenx Technologies Corp. (IGX.V)'s next earnings date?

IntelGenx Technologies Corp. (IGX.V) is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for IntelGenx Technologies Corp. (IGX.V)
.

How were IntelGenx Technologies Corp. (IGX.V)'s earnings last quarter?

IntelGenx Technologies Corp. (IGX.V) (CVE:IGX) issued its quarterly earnings data on Thursday, November, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm earned $0.68 million during the quarter.
View IntelGenx Technologies Corp. (IGX.V)'s earnings history
.

Who are some of IntelGenx Technologies Corp. (IGX.V)'s key competitors?

What other stocks do shareholders of IntelGenx Technologies Corp. (IGX.V) own?

Who are IntelGenx Technologies Corp. (IGX.V)'s key executives?

IntelGenx Technologies Corp. (IGX.V)'s management team includes the following people:
  • Dr. Horst G. Zerbe, Chairman, CEO & Chairman of Scientific Advisory Board (Age 73, Pay $233.65k)
  • Mr. André Godin C.A., CPA, CPA, CA, Pres & CFO (Age 56, Pay $216.31k)
  • Dr. Dana Matzen, VP of Bus. & Corp. Devel. (Age 42, Pay $166.19k)
  • Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp (Age 43, Pay $135.67k)
  • Ms. Ingrid Zerbe, Corp. Sec. (Age 66)
  • Stephen Kilmer, Investor Relations Officer
  • Mr. Rodolphe Obeid Ph.D., VP of Operations - IntelGenx Corp (Age 40)

What is IntelGenx Technologies Corp. (IGX.V)'s stock symbol?

IntelGenx Technologies Corp. (IGX.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IGX."

How do I buy shares of IntelGenx Technologies Corp. (IGX.V)?

Shares of IGX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What is IntelGenx Technologies Corp. (IGX.V)'s stock price today?

One share of IGX stock can currently be purchased for approximately C$0.32.

How big of a company is IntelGenx Technologies Corp. (IGX.V)?

IntelGenx Technologies Corp. (IGX.V) has a market capitalization of C$35.28 million and generates C$822,000.00 in revenue each year. IntelGenx Technologies Corp. (IGX.V) employs 48 workers across the globe.

What is IntelGenx Technologies Corp. (IGX.V)'s official website?

The official website for IntelGenx Technologies Corp. (IGX.V) is www.intelgenx.com.

How can I contact IntelGenx Technologies Corp. (IGX.V)?

The company can be reached via phone at 514-331-7440.

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.